
Loading, please wait...

Loading, please wait...

A pioneering study published in Alzheimer's Research & Therapy explores the potential of gamma magnetic stimulation as a non-invasive treatment for Alzheimer's disease (AD). While researchers previously investigated auditory and visual 40 Hz stimulation, this research focuses on pulsed magnetic fields. Specifically, the study examines how low-field magnetic stimulation (gamma-LFMS) affects cognitive function and brain pathology in transgenic mouse models. These findings offer a new perspective on neuromodulation for neurodegenerative disorders.
The research team utilized 9-month-old APP/PS1 mice to test the efficacy of this modality. They applied a magnetic field strength of 10 mT at a frequency of 40 Hz. Furthermore, the treatment protocol involved two 30-minute sessions daily for 18 consecutive days. Scientists primarily monitored spatial memory, hippocampal network changes, and amyloid protein levels during the trial. Notably, they aimed to determine if subthreshold magnetic pulses could entrain endogenous rhythms effectively without the need for sensory input.
The results demonstrate that the intervention improved spatial memory performance in the AD mice significantly. Additionally, the stimulation increased gamma band power and theta-gamma phase-amplitude coupling within the hippocampal CA1 region. Consequently, this suggests that gamma magnetic stimulation helps restore the rhythmic coordination necessary for healthy memory processing. Moreover, the researchers observed a marked reduction in hippocampal Beta-amyloid 42 (Aβ42) burden, which is a hallmark of Alzheimer’s pathology. Simultaneously, the treatment showed a trend toward desynchronization in the low gamma band.
This study addresses a major knowledge gap in neurostimulation research. By demonstrating that low-field magnetic pulses can ameliorate pathophysiological damage, it paves the way for accessible treatment options. Therefore, these findings provide a theoretical foundation for developing cost-effective, home-based devices. Such technology could potentially offer a scalable solution for managing dementia throughout the lifespan. In addition, clinicians should closely monitor emerging human trials involving similar LFMS protocols to evaluate safety and efficacy in patients.
It is a non-invasive technique that uses low-intensity magnetic fields pulsing at 40 Hz to stimulate brain rhythms associated with cognitive health and memory.
Unlike light or sound therapy, magnetic stimulation can reach deeper brain structures directly. It bypasses sensory pathways to entrain neural oscillations and potentially clear toxic proteins like amyloid-beta.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Zheng W et al. Gamma low field magnetic stimulation ameliorates pathophysiological damage and cognitive impairments in AD mice. Alzheimers Res Ther. 2026 Apr 18. doi: 10.1186/s13195-026-02052-1. PMID: 42001186.
Martorell AJ, et al. Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition. Cell. 2019;177(2):256-271.e22.
Geng D, et al. Experimental and computational study of 40 Hz low-field magnetic stimulation modulating neural activity and pathology in a mouse model of Alzheimer's disease. Exp Neurol. 2025 Oct 7;395:115494.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study shows that 40Hz gamma low field magnetic stimulation (gamma-LFMS) significantly reduces Aβ42 levels and improves memory in AD mice....
6 months ago

Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today

Demanding exhaustive hormonal profiling can inadvertently discourage clinical studies involving females. Methodological standards must align with the specific scientific question to expand, not restrict, equitable evidence for women.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

A novel calcium polyphosphate coacervate enables injectable bone implants with in situ hierarchical porosity via phase separation and gas foaming, significantly enhancing cell proliferation, energy metabolism, and osteogenic differentiation for minimally invasive bone defect repair.
Today

India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today